Navigation Links
Berkeley Lab scientists control light scattering in graphene
Date:3/16/2011

in which not charge but the quantum spins of electrons are affected. Strongly enhanced Raman scattering can be a boon to nanoscale materials research. Hot luminescence is potentially attractive for optoelectronics and biological research, in which near-infrared tags even weak ones could be very useful.

"Likewise the phenomenon of hot electron luminescence, because it immediately follows excitation by a probe laser, could become a valuable research tool," says Wang, "particularly for studying ultrafast electron dynamics, one of the chief unusual characteristics of graphene."


'/>"/>

Contact: Paul Preuss
paul_preuss@lbl.gov
510-486-6249
DOE/Lawrence Berkeley National Laboratory
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology technology :

1. Strange new twist: Berkeley researchers discover Möbius symmetry in metamaterials
2. Berkeley Law Survey Challenges Popular Beliefs About Hi-tech Startup Patents
3. Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley
4. Berkeley Lab scientists create molecular paper
5. LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production
6. Berkeley researchers take the lead out of piezoelectrics
7. Berkeley researchers find new route to nano self-assembly
8. DOE to Explore Scientific Cloud Computing at Argonne, Lawrence Berkeley National Laboratories
9. Now, the story can be told how scientists helped ID Amerithrax
10. Laboratory-grown urethras implanted in patients, scientists report
11. Cellular Dynamics International Scientists Report on Efficient Method to Produce Footprint-Free Induced Pluripotent Stem Cells (iPSCs) Under Feeder-Free Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Berkeley Lab scientists control light scattering in graphene
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... a selective thyroid hormone receptor beta agonist, reduced levels ... ... Mich., Jan. 29 QuatRx Pharmaceuticals, a,privately-held biopharmaceutical company developing ... today,announced results from two Phase 1 clinical studies with its ...
... end; no equity financings expected in 2008, - ... in,2008; latest data for all programs to be presented ... of research and development investment in pharmacological, chaperone ... CRANBURY, N.J., Jan. 29 Amicus Therapeutics,(Nasdaq: ...
... - Viventia Biotech Inc., a privately held,biopharmaceutical ... focused on cancer, announced today it intends ... realize value from its,pipeline of therapeutic antibodies, ... capabilities. The Company will consider potential,strategic opportunities ...
Cached Biology Technology:Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels 2Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 2Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 3Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 4Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 5Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 6
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... February 21, 2013 A new study published in ... Pathology suggests that cortical type 2 cannabinoid (CB2) ... ischemia. Researchers found that the cannabinoid trans-caryophyllene ... in both in vivo and in vitro animal models. ...
... Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology at ... a new mutation in a gene that causes Schnyder corneal ... vitamin K metabolism suggesting the possibility that vitamin K may ... published in the February 2013 issue of the peer-reviewed journal, ...
... The Entomological Society of America (ESA) and the ... new partnership that will provide ESA members with an ... The ESA is the largest organization ... of entomologists and individuals in related disciplines. Founded ...
Cached Biology News:Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury 2Research discovers gene mutation causing rare eye disease 2Entomological Society of America launches science policy program 2
... to reward the animal for foraging behavior.The Spatial ... built around a video camera, frame grabber, and ... fields at once and up to 6 moving ... records them, but also allows video replay of ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 1-year license ... NFP/Academic accounts ,one CD-ROM containing ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
Biology Products: